QIAGEN's QIAstat-Dx Rise Receives FDA Clearance, Boosts Diagnostics Portfolio and Stock Potential
ByAinvest
Wednesday, Sep 3, 2025 10:29 am ET1min read
QGEN--
QIAGEN's QIAstat-Dx Rise system, cleared by the FDA, offers enhanced throughput and ease of use for hospitals and reference laboratories. The system can run up to 160 tests per day and is already available in over 100 countries with over 4,600 instruments placed globally. QIAGEN plans to add gastrointestinal panels to the system in the coming months. The syndromic multiplex diagnostics market is expected to grow at a CAGR of 3.9% through 2030, favoring QIAGEN's prospects.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet